TECHNIQUES AND PROCEDURES

Expansion of Primary Bronchial Epithelial Cell Cultures

G. Margarit, J. Belda, P. Casan, and J. Sanchis
Departamento de Neumología, Hospital de la Santa Creu i de Sant Pau, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.

In vitro models based on primary cultures of human bronchial epithelial cells (BEC) are difficult to develop. A primary culture is established from explants of samples taken from operated patients or autopsies or it may be started from fragments obtained from bronchoscopic biopsies, although such fragments are small and, therefore, yield few BEC. In response to the difficulty of obtaining a sufficient number of cells for more complex experiments, commercial BEC lines have been developed, but such cell lines do not always provide the genotype needed for the disease under study.

The aim of the present work was to develop a method for increasing the production of primary cultures of human BEC. The method sought would allow repeated performance of complex studies on explants from samples obtained from a single patient by bronchoscopy or thoracic surgery.

Método para amplificar cultivos primarios de células epiteliales bronquiales

OBJETIVO: Los cultivos celulares son un buen modelo para el estudio de las enfermedades pulmonares, pero son difíciles de reproducir y producen un número limitado de células. El objetivo de este estudio ha sido desarrollar un método que incrementase la producción de células epiteliales bronquiales (CEB) humanas en cultivos primarios.

MATERIAL Y MÉTODOS: Se procesó un total de 12 muestras (9 procedentes de muestras quirúrgicas y 3 de biopsias endoscópicas) en placas recubiertas de colágeno tipo I con medio suplementado para CEB. Al iniciarse la proliferación celular a su alrededor, los explantes se extrajeron y subculturaron sucesivamente. Las células restantes se dejaron proliferar y se tripsinizaron tras alcanzar más del 50% de confluencia. Se valoraron el número de células obtenidas, la viabilidad y la citoqueratina 7. 

RESULTADOS: El número total de células obtenidas con este método superó en una media de 3 veces el número de CEB humanas obtenidas en cultivos primarios simples. El número máximo de subcultivos fue de 5, la viabilidad media (± desviación estándar) fue de 91,9 ± 11,7% y el porcentaje de células positivas para la citoqueratina 7 del 30,71 ± 10,68%.

CONCLUSIONES: El método descrito para amplificar cultivos primarios de CEB permite incrementar la producción de células obtenidas.


This study was partially funded by Red-Respira-ISCIII-RTIC-03/11.

Correspondence: Dra. G. Margarit.
E-mail: gmargarit@hsp.santpau.es

Manuscript received January 14, 2005. Accepted for publication February 1, 2005.
Material and Methods

Sample Harvesting

Samples came from patients who underwent surgical resection or bronchoscopy under normal conditions according to standard protocols for their diseases. The patients were informed about the type of procedure to be performed and gave their signed consent to the study, which was approved by the hospital ethics committee.

Thoracic Surgery

Nine patients undergoing thoracic surgery to remove tumors were included. A small fragment of uninvolved tissue was removed from the resected material, distal to the tumor.

Bronchoscopy

Three patients who underwent bronchoscopy were included. A bronchoscopy forceps was used to biopsy the main carina of each patient under the assumption that that site would be unaffected by disease.

Cell Cultures

The culture medium and final concentrations of solutions were prepared as described by Devalia et al.2 as follows. Tissue culture medium 199 with L-glutamine was supplemented with insulin to a concentration of 2.5 µg/mL, with cortisone to a concentration of 0.361 µg/mL of hydrocortisone, and with apotransferrin to 2.5 µg/mL (Sigma Chemical Co, St Louis, Missouri, USA). Nu-serum IV (Becton Dickinson, Bedford, Massachusetts, USA) was used at a concentration of 2.5%. The concentration of epidermal growth factor (Becton Dickinson) was 20 ng/mL. Also used were 1% penicillin-streptomycin (Life Technologies, Gibco BRL, Grand Island, New York, USA) and amphotericin B at a concentration of 2 µg/mL. (Squibb Industria Farmacéutica SA, Esplugues de Llobregat, Barcelona, Spain).

Epithelial Cell Harvesting

The greatest number of explants that could be scraped from the internal bronchial wall of each surgically removed block were taken with the help of forceps and scalpel. Endoscopic biopsies were divided into fragments or explants. All explants measured 1 by 2 mm. Explants were washed with normal saline solution (sodium chloride 0.9%) with 1% penicillin-streptomycin. Cells were counted and checked for viability in 10 µL of the suspension by the trypan blue (0.4%) exclusion method (Sigma Chemical Co) in a Neubauer chamber.

Immunocytochemical Staining for Cytokeratin 7

The cells were stained with primary monoclonal mouse anti-human cytokeratin 7 antibody and secondary peroxidase-labeled goat anti-mouse-immunoglobulin G antibody. The chemical reaction was started with 3,3′-diaminobenzidine substrate for peroxidase and stained with Harris’s hematoxylin for contrast. The material for immunocytochemistry was supplied by DAKO Corp (Carpinteria, California, USA). The percentage of cells positive for anticytokeratin 7 was calculated. At the same time, a paraffin block containing healthy bronchial cells was prepared and slices were stained by immunohistochemistry to calculate the percentage of cytokeratin 7 positive cells. Fibroblast cultures were the negative controls.

Statistical Analysis

Analyses were carried out with the Statistical Package for the Social Sciences (SPSS) version 10.0 from 1999. Mean (SD) values for each variable were calculated.

Results

Twelve samples were harvested: 9 from thoracic surgical resections and 3 from bronchoscopic procedures. The 11 men and 1 woman had a mean age of 65 (12) years. All patients were smokers or ex-smokers. Mean forced expiratory volume in the first second was 70% (13%) of the theoretical value and 5 patients had received chemotherapy. Results are shown case by case in Table 1.

The mean number of explants obtained was 18.1 (14) from surgical resections and 6 (1.2) from bronchoscopic biopsies. The explants from cultivated samples were passaged a mean 3.4 times (range, 2–5 subcultures). Fragments from surgical resections gave better results than those from bronchoscopic procedures. Table 2 shows the mean yield from each passage.

The mean number of BEC (in millions) obtained was 2.42 (4.08)—specifically 3.18 (4.5) for samples from resective surgery and 0.15 (2.2) from bronchial biopsies. The mean expansion obtained, expressed as a percentage of the primary cultures, was 300% (143%)—specifically 343% for bronchial biopsies and 200% for surgical resections. Overall mean cell viability was 91.9%.
specifically 92.1% (10.3%) for thoracic surgery samples and 90.47% (18.9%) for bronchoscopic biopsies. Yield, defined as obtaining an elevated number of viable BEC, varied from one passage to another. Yield was higher in the initial passages and decreased as the explant aged.

Immunocytochemical analysis showed a mean 30.71% (10.68%) of cells to be positive for cytokeratin 7. The mean for the positive control was 59.2%. In later passages, there was a slight tendency for the number of cells positive for cytokeratin 7 to decrease.

Discussion

Although the culture technique we describe has been mentioned in the literature, this is the first time it has been described in detail and applied to the expansion of BEC cultures. This expansion method facilitates larger scale experiments and increases the number of tests that can be performed on cells from each sample, given that the number of BEC obtained from each primary culture is 3-fold greater than the number yielded by simple culturing. There is greater BEC growth in the first passages and less in later ones. Although viability does not vary over the course of processing, cell quality decreases, as reflected by the decrease in cytokeratin 7 positivity. It would seem that BEC from thoracic surgical samples and bronchoscopy samples would behave similarly in this regard. However, that was not the case for the number of passages possible. One explanation for this might be small sample size, which meant that few explants were cultured. Results obtained from bronchoscopy samples were somewhat different from those of surgical samples in the present study and possibly they should not be considered together.

Other protocols for culturing BEC described in the literature involve the processing of organs, explants, or dissociated cells. When organs are cultured, BEC are accompanied by other nonepithelial cell types such as fibroblasts and endothelial, inflammatory, and muscle cells that might interfere with some experiments. Some authors prefer to perform enzyme disaggregation of the tissue to isolate BEC. Such detachment may cause biochemical and structural changes that would prevent cells from differentiating and maturing properly up to the final ciliated form.

For cultivation, BEC require a substrate that cells can attach to. Of the various techniques for coating dishes described in the literature, for this study we chose collagen as the medium for BEC growth. There is no consensus on whether or not to add serum to the medium. Jorissen et al noticed that high serum concentrations (10%–20%) inhibited growth and induced squamous differentiation, whereas using serum-derived products such as NU-serum or Ultroser G supported successful cultures of nasal epithelial cells. Immunocytochemical staining with anti-cytokeratin 7 is a highly effective way to characterize cell origin. Normal human tracheal epithelial cells express that polypeptide, and the method has been used in pathology for discriminating between primary and metastatic lung tumors. This staining has also been used in vitro by

<table>
<thead>
<tr>
<th>Case</th>
<th>Explants</th>
<th>Passages for Subculturing</th>
<th>Total Cells (×10⁶)</th>
<th>Expansion, %</th>
<th>Viability, Mean (SD)</th>
<th>Cytokeratin 7, Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>4</td>
<td>0.98</td>
<td>360</td>
<td>90.10 (10.05)</td>
<td>29.50 (35.64)</td>
</tr>
<tr>
<td>2</td>
<td>10</td>
<td>4</td>
<td>1.48</td>
<td>120</td>
<td>92.51 (10.25)</td>
<td>32.60 (24.50)</td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>2</td>
<td>0.66</td>
<td>130</td>
<td>99.30 (1.20)</td>
<td>25.35 (3.18)</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
<td>2</td>
<td>0.89</td>
<td>210</td>
<td>96.00 (4.90)</td>
<td>39.10 (24.38)</td>
</tr>
<tr>
<td>5</td>
<td>23</td>
<td>5</td>
<td>2.40</td>
<td>250</td>
<td>92.20 (8.25)</td>
<td>33.40 (16.02)</td>
</tr>
<tr>
<td>6</td>
<td>16</td>
<td>4</td>
<td>2.36</td>
<td>110</td>
<td>97.30 (4.40)</td>
<td>12.92 (11.72)</td>
</tr>
<tr>
<td>7</td>
<td>44</td>
<td>4</td>
<td>1.55</td>
<td>250</td>
<td>87.42 (21.03)</td>
<td>35.80 (13.13)</td>
</tr>
<tr>
<td>8</td>
<td>7</td>
<td>2</td>
<td>0.02</td>
<td>200</td>
<td>75.00 (35.36)</td>
<td>15.60 (0)</td>
</tr>
<tr>
<td>9</td>
<td>5</td>
<td>2</td>
<td>0.32</td>
<td>230</td>
<td>100.00 (0)</td>
<td>54.53 (20.72)</td>
</tr>
<tr>
<td>10</td>
<td>5</td>
<td>2</td>
<td>0.12</td>
<td>600</td>
<td>91.70 (11.8)</td>
<td>30.30 (10.61)</td>
</tr>
<tr>
<td>11</td>
<td>37</td>
<td>4</td>
<td>4.33</td>
<td>400</td>
<td>91.14 (9.16)</td>
<td>30.96 (7.10)</td>
</tr>
<tr>
<td>12</td>
<td>14</td>
<td>2</td>
<td>0.65</td>
<td>140</td>
<td>83.93 (3.94)</td>
<td>28.50 (0)</td>
</tr>
</tbody>
</table>

*Total cell count is the sum of cells obtained from all passages.
†Viability and cytokeratin 7 values, respectively, are given as the mean (SD) percentage growth observed at each passage and as the percentage of positive cells.

<table>
<thead>
<tr>
<th>Passage</th>
<th>N</th>
<th>Explants</th>
<th>Viable Explants</th>
<th>Cells</th>
<th>Viability</th>
<th>Cytokeratin 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>12</td>
<td>15 (13.25)</td>
<td>13.67 (12.29)</td>
<td>1.66×10⁶ (3.59×10⁶)</td>
<td>94.63 (5.96)</td>
<td>28.27 (11.26)</td>
</tr>
<tr>
<td>1</td>
<td>12</td>
<td>14.42 (13.47)</td>
<td>11.17 (10.62)</td>
<td>0.33×10⁶ (0.35×10⁶)</td>
<td>89.92 (14.9)</td>
<td>36.71 (13.81)</td>
</tr>
<tr>
<td>2</td>
<td>12</td>
<td>12.75 (10.65)</td>
<td>5.8 (6.85)</td>
<td>0.27×10⁶ (0.38×10⁶)</td>
<td>90.29 (8.9)</td>
<td>31.55 (23.59)</td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>14.5 (7.7)</td>
<td>8.33 (6.06)</td>
<td>0.3×10⁶ (0.37×10⁶)</td>
<td>97.82 (3.92)</td>
<td>30.9 (18.64)</td>
</tr>
<tr>
<td>4</td>
<td>6</td>
<td>12.5 (6.95)</td>
<td>4.17 (3.54)</td>
<td>0.03×10⁶ (0.04×10⁶)</td>
<td>85.96 (21.88)</td>
<td>25.2 (1.7)</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

*Viability and cytokeratin 7 values, respectively, are given as the mean (SD) percentage growth observed at each passage and as the percentage of positive cells.
Sapsford et al\textsuperscript{7} to characterize glandular epithelial cells and to demonstrate that the structural and biochemical features of BEC are preserved. In that study, 39.8\% (0.95\%) of the growth in cultures corresponded to glandular epithelial cells. That figure was very similar to the 30.71\% (10.68\%) we report in the present paper.

In conclusion, the method we propose increases the number of human BEC yielded by primary cultures 3-fold on the average. That increase allows complex studies to be carried out and repeated in contexts requiring a large number of cells from explants from a single patient’s bronchoscopy biopsy or surgically excised tissue.

Acknowledgments

The authors would like to express gratitude to R.J. Sapsford for providing details on the culture method and to colleagues in the thoracic surgery and bronchoscopy services of the respiratory medicine department of Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, for their provision of samples for this study.

REFERENCES